Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 4/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 4/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26810269 | 0.93 | TP53 (0.38) | KMT2AKDM4EMAPTCCR2AURKA | |
| SCHEMBL26810260 | 0.92 | EGFR (0.37) | KMT2AMAPTCCR2AURKAAURKB | |
| SCHEMBL26810270 | 0.91 | AURKA (0.37) | LOXL2MAPTAURKAAURKB | |
| SCHEMBL26810139 | 0.91 | CCR2 (0.37) | LOXLOXL2KMT2AALDH1A1KDM4E | |
| SCHEMBL24310100 | 0.91 | USP2 (0.39) | HPGDALDH1A1CCR2AURKAAURKB | |
| SCHEMBL26810171 | 0.91 | MAPT (0.40) | LOXLOXL2KMT2AMEN1HPGD | |
| SCHEMBL29566721 | 0.91 | PTK2 (0.39) | LOXLOXL2KMT2AMEN1HPGD | |
| SCHEMBL26812018 | 0.91 | PTK2 (0.39) | LOXLOXL2KMT2AMEN1HPGD | |
| SCHEMBL26810272 | 0.90 | EGFR (0.38) | KMT2AMEN1HPGDALDH1A1MAPT | |
| SCHEMBL29566957 | 0.89 | SLC6A9 (0.39) | LOXLOXL2ALDH1A1KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | LOX 2571/4885LOXL2 2934/4885KMT2A 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.